about
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†Time for more optimism in metastatic breast cancer?Over-treatment in metastatic breast cancer.Phyllodes tumor of the breast.A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC).Cardiovascular effects of systemic cancer treatment.1st International consensus guidelines for advanced breast cancer (ABC 1).Breast cancer in 2014: A call back to reality!Management of locally advanced breast cancer-perspectives and future directions.Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives.Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).Epithelioid sarcoma of the Bartholin's gland primarily diagnosed as vulvar carcinoma.Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98.Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients.International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer.Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259].Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3).Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer.Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Corrigendum: Management of locally advanced breast cancer--perspectives and future directions.Are bilateral breast cancers different from breast cancers coexisting with ovarian cancer? An immunohistochemical analysis aimed at intrinsic tumor phenotype.Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis focused on cell cycle regulation.3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).New horizon in breast cancer therapy: highlights from the European Society for Medical Oncology.Response: Re: International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent ChemotherapyPrevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening†Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upLocally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upChanges in lateral dimensions of irradiated volume and their impact on the accuracy of dose delivery during radiotherapy for head and neck cancerSecond lower genital tract squamous cell carcinoma following cervical cancerPatient-related factors determining geometry of intracavitary applicators and pelvic dose distribution during cervical cancer brachytherapyAlveolar Rhabdomyosarcoma of the Uterine CervixAre bilateral breast cancers and breast cancers coexisting with ovarian cancer different from solitary tumors? A pair-matched immunohistochemical analysis aimed at intrinsic tumor phenotypeSynchronous and metachronous metastatic breast cancer--two incarnations of the same beast?Breast cancer units--improvement in care or expensive "wishful thinking"?
P50
Q30313649-E08AC253-F027-43F5-9AF5-E870E4AFB2C5Q30317064-D85EA41D-CFD8-496E-AE37-4B378605DDEDQ30317067-6DE3CE7D-2E79-4E87-9D73-873E5FF90A11Q30354522-93EB8F0C-E62B-4EA7-BB12-240C17E8C99DQ30390926-A0015A09-BD58-4E45-8A74-079F958E3CA5Q34583689-0A8D9E1D-3302-41A9-824C-92A9DA21B0DEQ36616511-97B3C8D7-0959-455C-89FE-8F916413914FQ37815319-E384A6D8-3E5A-4DC0-AB22-242006C76D1FQ37994463-99BB3550-B504-42A7-83BC-63BE79E49A32Q38308031-C15294E0-397E-4300-A440-D8EFDB05CF64Q38350939-385496D1-A2A8-48A1-9C25-8E4107965EF0Q38770448-6414C8E3-1BBB-4E48-9748-B65FE853D5A5Q39161262-0557ACD3-8A81-4A9F-91A6-22CB70DB68FBQ39230994-8E51955D-6D78-4802-BD0E-E8B806DDF39DQ39349856-371F396B-C5B4-47AD-A749-BF1B9CE8A2D0Q41646402-0E6E5F24-F076-490A-9D46-D036F47FE62EQ42595848-830EFEC6-2E7A-42B0-B80A-654D95FB1759Q44368041-D97003C4-F0BC-4A1B-85D4-E4FEAE3A92D2Q46614267-47E43163-6822-4B43-843C-5B0D91D89ECDQ46736552-7B05FB64-6B8C-4EFA-82E9-934CA99DE1C4Q47293093-8D00F4FF-D9F9-454F-A646-394CE826C68FQ47568177-4810D888-87B1-4D84-8973-95F6D13D5934Q48293335-1F06894F-C3A7-44E9-A289-DF2BB0E6A852Q48518242-C4BFABF2-2947-46E9-8DBF-199DB9FD88CFQ51020917-748BBCB8-8932-473E-B594-D2638B8DF15AQ51104988-5558D9F9-7B87-4ED4-A17D-436C231B5A6CQ51827397-EF762B30-A4A4-4A89-B934-D5F3093C0C01Q53738984-F704C7C1-764B-4A19-B95F-F98A020E0222Q54185643-494F9F8E-ACD4-4B17-8CC6-5F12FA0197E4Q57391566-EB97A9F7-CF9A-49DA-836F-7A21CC379C29Q59273721-225C14B2-F6C2-46B5-AEB8-F7E89132A3DFQ59567316-7355F6CA-CE53-4A6B-A0DC-AEC6522827A3Q59567521-09BF8F5F-1F9E-4DC7-953D-CE15D8F766FDQ60189438-AAA2DCF2-524F-4D24-A8C2-B31F77CDDCFCQ60189500-4BD560AD-7653-4FCA-90FF-EF4672CE63BCQ60189523-66F92A3D-8A8C-4451-BCCF-3AFBA750C5C2Q60189541-99AD6783-518C-4BF8-A100-401E3E80CF17Q85716451-8D9E712F-B167-46D7-8C0F-5423EDAE12BFQ86553214-EF70A837-87E7-489E-A7F0-6843B776AAA9Q87630959-AE975C3D-B913-437B-9C01-657FA7D5426B
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Elżbieta Senkus
@ast
Elżbieta Senkus
@en
Elżbieta Senkus
@es
Elżbieta Senkus
@nl
Elżbieta Senkus
@pl
Elżbieta Senkus
@sl
type
label
Elżbieta Senkus
@ast
Elżbieta Senkus
@en
Elżbieta Senkus
@es
Elżbieta Senkus
@nl
Elżbieta Senkus
@pl
Elżbieta Senkus
@sl
altLabel
Elżbieta Senkus-Konefka
@en
prefLabel
Elżbieta Senkus
@ast
Elżbieta Senkus
@en
Elżbieta Senkus
@es
Elżbieta Senkus
@nl
Elżbieta Senkus
@pl
Elżbieta Senkus
@sl
P214
P244
P106
P1153
35576852100
P21
P213
0000 0004 0826 3243
P214
P244
n2018185335
P31
P3124
P496
0000-0001-6855-397X
P734
P735
P7859
lccn-n2018185335